Chemotherapy-associated peripheral neurotoxicity of erythroxylanes
Conditions
Interventions
Test group: Tongluohuoxue Formula:From the first day of paclitaxel-based chemotherapy, patients should receive Tongluohuoxue Formula at the same time. 2 sachets should be used each time, and the solut
Control group: Tongluohuoxue placebo:From the first day of paclitaxel-based chemotherapy, patients should receive Tongluohuoxue Formula placebo at the same time. 2 sachets should be used each time, an
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Age =18 years old, male and female are not limited. 2. Able to cooperate with the completion of the scale and follow-up visits 3. Patients with malignant tumors who are scheduled to receive chemotherapy with violet alkanes and have not yet received it.
Exclusion criteria
Exclusion criteria: 1. Those with a history of compression-induced neuropathy (e.g., carpal/tarsal tunnel syndrome, neuropathy, spinal stenosis, brachial plexus neuropathy) 2. Patients with diabetes and peripheral vascular disease 3. Patients with brain or meningeal metastases 4. Patients with significant hepatic and renal abnormalities 5. Patients with previously diagnosed neurological lesions. 6. Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FACT-Ntx subscale; | — |
Secondary
| Measure | Time frame |
|---|---|
| NCI-CTCAE Classification;EORTC QLQ-CIPN20 scale; | — |
Countries
China
Contacts
Public ContactLizhu Lin
Lingnan Cancer Institute, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Outcome results
None listed